Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a BetZacks Investment Research • Thursday
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to TradeZacks Investment Research • 08/20/24
CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024GlobeNewsWire • 08/07/24
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024GlobeNewsWire • 05/06/24
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?Zacks Investment Research • 05/02/24
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)GlobeNewsWire • 04/15/24
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should KnowZacks Investment Research • 04/11/24
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America ConferenceGlobeNewsWire • 04/11/24
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/12/24
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024GlobeNewsWire • 03/06/24